Representative Patents and Published Applications

  • U.S. Patent 11,879,020 – Cyclic Peptidomimetic for the Treatment of Neurological Disorders (Assignee: Brown University)
  • U.S. Patent 11,738,020 – Stable Liquid Vigabatrin Pharmaceutical Composition for Oral Dosage (Assignees: FTF Pharma; LM Manufacturing Ltd.)
  • U.S. Patent 11,684,781 – Brain Implantable Device (Assignee: Brown University)
  • U.S. Patent 11,674,142 – Methods and Compositions for Treating, Preventing or Reversing Obesity and Obesity-Related Disorders by Opsin 3 Regulation of Hypothalamic Melanocortin Receptors (Assignee: Brown University)
  • U.S. Patent 11,504,515 – Access Port System with Self-Adjusting Catheter Length (Applicant: Imotik BioSolutions LLC)
  • U.S. Patents 11,479,576 and 10,745,435 – Nucleic Acid Prodrugs (Assignee: Avalo Therapeutics, Inc.)
  • U.S. Patents 11,479,542, 10,710,976, and 10,202,363 – Compounds, Compositions and Methods (Assignees: Cerecor, Inc.; Merck Sharp & Dohme Corp.)
  • U.S. Patents 11,345,652, 10,618,870, and 10,556,853 – Anticonvulsant Compounds (Assignee: Owen-Barry Pharmaceuticals Inc.)
  • U.S. Patent 11,242,374 – Minimally-Invasive and Activity-Dependent Control of Excitable Cells (Assignees: Brown University; Central Michigan University)
  • U.S. Patent 10,448,877 – Methods for Prediction and Early Detection of Neurological Events (Assignees: Brown University; The General Hospital Corporation; The U.S. Government as Represented by the Department of Veterans Affairs)
  • U.S. Patent 10,441,160 – Method and System for Classifying Optic Nerve Head (Assignee: Delphinium Clinic, Ltd.)
  • U.S. Patent 10,433,754 – Implantable Wireless Neural Device (Assignee: Brown University)
  • U.S. Patent Application 2020/0367749 – Implantable Wireless Network of Distributed Microscale Sensors (Assignees: Brown University; University of California)
  • U.S. Patent Application 2020/0038651 – Neural Interrogation Platform (Assignee: Brown University)
  • U.S. Patent Application 2018/0134763 – Brain Penetrant Amylin Receptor Based Peptides for Alzheimer’s Disease (Assignee: The Governors of the University of Alberta)
  • WO 2020/214987 – Neurogenesis (Assignee: Brown University)
  • WO 2020/102516 – Access Port System with Self-Adjusting Catheter Length (Applicant: Imotik BioSolutions LLC)
  • WO 2020/051206 – Compositions and Methods for the Modulation of CRFBP and the Treatment of Alcoholism (Assignee: Brown University)
  • U.S. Patent Application 2018/0000611 – Lumbar Fusion (Assignee: Massengale)
  • WO 2016/030823 – Deep Brain Stimulation Lead (Applicant: Aleva Neurotherapeutics SA)°
  • WO 2016/030822 – Leadless Neurostimulator (Applicant: Aleva Neurotherapeutics SA)°
  • WO 2015/173787 – Device for Interacting with Neurological Tissue and Methods of Making and Using the Same (Applicant: Aleva Neurotherapeutics SA)°
  • WO 2010/014686 – Apparatus and Method for Optimized Stimulation of a Neurological Target (Applicant: Aleva Neurotherapeutics SA)°
  • U.S. Patent Application 2013/0090374 – Methods for the Treatment of Tay-Sachs Disease, Sandhoff Disease, and GM1-Gangliosidosis (Applicant: National Tay-Sachs & Allied Diseases Associations Inc.)°
  • U.S. Patent 8,774,937 – Microfabricated Surface Neurostimulation Device and Methods of Making and Using the Same (Assignee: École Polytechnique Fédérale de Lausanne)°
  • U.S. Patent 8,346,366 – Spinal Cord Implant Systems and Methods (Assignee: Lahey Clinic Foundation, Inc.)°
  • U.S. Patent 7,381,745 – Ligands for Metabotropic Glutamate Receptors and Inhibitors of NAALADase (Assignee: Georgetown University)°
  • U.S. Patent 7,335,347 – Methods for Purifying Radiolabelled Compounds (Assignee: McMaster University)°
  • U.S. Patent 7,317,103 – Imaging Agents for Diagnosis of Parkinson’s Disease (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 7,141,573 – Polypharmacophoric Agents (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 7,052,913 – Matrices for Drug Delivery and Methods for Making and Using the Same (Assignee: Molecular Insight Pharmaceuticals, Inc.)°
  • U.S. Patent 6,444,702 – Aminoadamantane Derivatives as Therapeutic Agents (Assignee: NeuroMolecular, Inc.)°
  • U.S. Patent 6,407,204 – Use of Conantokins for Producing Analgesia or for Neuoprotection (Assignee: CytoTherapeutics, Inc.)°
  • U.S. Patent 6,077,823 – Method for Reducing Tissue Damage Associated with Ischemia-Reperfusion or Hypoxia Injury (Assignee: Creative BioMolecules, Inc.)°
  • U.S. Patent 5,986,055 – CDK2 Interactions (Assignee: CuraGen Corporation)°
  • U.S. Patent 5,853,717 – Methods and Compositions of Growth Control for Cells Encapsulated Within Bioartificial Organs (Assignee: CytoTherapeutics, Inc.)°

°Denotes representations that were handled by a member of Adler’s Life Sciences team prior to joining Adler Pollock & Sheehan, P.C.

Back to Top